Acknowledgement: We wish to gratefully acknowledge an educational grant from Sanofi Aventis for this course.

The cases will include differential diagnoses, pathogeneses, and treatment approaches and will illustrate the role of the primary care provider and the oncologist in the management of this disease. Prostate, colorectal, breast, and lung cancers will be discussed. This online course guides the participant through clinical material in an engaging and interactive format.

NUMBER OF CREDIT HOURS: The Harvard Medical School designates this educational activity for a maximum of 5 AMA PRA Category 1 credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

COST: $100.00
click here for pricing outside the United States of America

OVERALL LEARNING OBJECTIVES:

1. Review the benefits and risks of various androgen deprivation therapies in the setting of metastatic prostate cancer
2. Discuss the options available for the treatment of hormone refractory metastatic prostate cancer
3. Demonstrate several chemotherapeutic approaches to the treatment of metasatic colon cancer
4. Examine the role of resection as well as targeted antibody agents in addressing metastatic colon cancer
5. Illustrate the role of taxanes and anthracyclines in the setting of metastatic breast cancer
6. Describe the usage of monoclonal antibodies and biologic modifiers for metastatic breast cancer
7. Discuss the coordination of medical oncology and radiation oncology in addressing metastatic lung cancer
8. Assess the various first, second and third-line chemotherapy treatments for metastatic lung cancer

back to the top

STEVEN COME, MD Course Co-Director

Dr. Come is Medical Director of the Breast Cancer Program and Director of the Hematology-Oncology Ambulatory Unit at Beth Israel Deaconess Medical Center in Boston. He is an Associate Professor of Medicine at Harvard Medical School and a member of the Breast Cancer program and the Breast SPORE at the Harvard/Dana Farber Cancer Center. Dr. Come received his MD at Harvard and served as intern, resident, and chief resident in medicine at the Beth Israel Hospital in Boston. He was a Clinical Associate in the Medicine Branch of the National Cancer Institute. Dr. Come’s research interests include the integration of therapies for early breast cancer and optimizing endocrine therapy for this disease. He is presently focussing on the development of new hormonal and biologic agents, cross talk between endocrine and growth factor pathways, and presurgical models to better evaluate breast cancer biology. He has been a principal and co-investigator on numerous Harvard, industry-sponsored, and cooperative group trials. DISCLOSURE: Company: Astra Zeneca; Novartis; Pfizer Type of Relationship: Research Funding Consultant; Consultant; Consultant

MARC GARNICK, MD Course Co-Director

Dr. Marc B. Garnick is an internationally renowned expert in medical oncology and urologic cancer. He has dedicated his career to the development of new therapeutic programs for the treatment of cancer patients and has maintained a clinical practice at the Beth Israel Deaconess Medical Center. He is Clinical Professor of Medicine and a member of the active teaching faculty at Harvard Medical School. Dr. Garnick received his undergraduate degree from Bowdoin College and his medical degree from the University of Pennsylvania School of Medicine and completed his internal medicine internship and residency at the University's Hospital. He has also completed a research and clinical fellowship in metabolism with the National Institutes of Health (NIH) and a medical oncology fellowship at the Dana Farber Cancer Institute of Harvard Medical School where he also served on the faculty. He is a member of numerous professional organizations, as well as several editorial boards for peer-reviewed publications including Harvard Men’s Health Watch. Dr. Garnick has authored more than 350 peer-reviewed articles and reviews on clinical research, drug development and cancer biology and has authored or edited 6 books. Most recently, he co-authored an article entitled "Combating Prostate Cancer" which appeared in Scientific American, and authored the evidence-based prostate cancer screening policy guidelines for the American College of Physicians as part of their educational resource for primary care physicians and internists. He has written a book entitled A Patient's Guide to Prostate Cancer, now undergoing its third edition. Dr. Garnick currently serves as the Medical Advisor to the World Book Encyclopedia. Dr. Garnick was the academic principal investigator on the development of Lupron, a widely used hormonal therapy for prostate cancer. Most recently, he directed the clinical development of a novel hormonal therapy recently approved by the FD DISCLOSURE: Company: Harvard Medical School-Harvard Health Publications, SEP Type of Relationship: Editor in Chief of Perspectives on Prostate Disease, Consultant Content Area:

JEFFREY MEYERHARDT, MD, MPH Course Co-Director

Dr. Meyerhardt is an Associate Physician of the Department of Medical Oncology at the Dana-Farber Cancer Institute, member of the Gastrointestinal Cancer Center and Assistant Professor of Medicine at Harvard Medical School. Dr. Meyerhardt conducts outcomes research in patients with gastrointestinal cancer, particularly the relationship between diet and lifestyle on patients with colorectal cancer. In addition, he has served as lead investigator and co-investigator of multiple clinical trials for patients with gastrointestinal cancers. Dr. Meyerhardt received his undergraduate degree from Haverford College, medical degree at Yale School of Medicine and Masters of Public Health at the Harvard School of Public Health. DISCLOSURE: Sanofi-aventis: Consultant (<10 K/year): Treatment

LOWELL E. SCHNIPPER, MD Course Co-Director

Bio and Photo Coming Soon. DISCLOSURE:

ZSOFIA K. STADLER, MD Course Contributor

Dr. Stadler is a graduate of the Weill Medical College of Cornell University and has completed the Clinical Effectiveness Program at the Harvard School of Public Health. She received her internal medicine training at Brigham and Women's Hospital and subsequently completed her hematology/oncology fellowship at Beth Israel Deaconess Medical Center. Her research interests focus on the identification, genetic evaluation and medical management of patients with a hereditary predisposition to cancer. DISCLOSURE:

back to the top

STEPHEN A. CANNISTRA, MD Reviewer

Dr. Cannistra is the Director of Gynecologic Medical Oncology and is an accomplished scholar in gynecologic malignancies, with a national and international reputation in the field of ovarian cancer. His group’s research efforts focus on the development of novel approaches to the treatment of newly diagnosed and relapsed ovarian cancer. Several investigator-initiated trials have already been developed in his program, including the use of an oral VEGF-R inhibitor for treatment of marker-only relapse, as well as consolidation approaches using oral topotecan in patients who have achieved complete clinical remission. Current clinical trials are designed to target the angiogenic pathway, using bevacizumab in combination with first-line chemotherapy, or as a single agent in relapsed disease. More recently, his group was the first to identify a microarray gene expression profile, referred to as the OCPP, that has powerful and independent prognostic value in ovarian cancer. His group's ongoing work in this area has revealed other gene expression patterns which are predictive of response to chemotherapy, as defined by the results of second-look laparoscopies. This work is made possible through the use of a large ovarian cancer tissue bank and correlative clinical database that Dr. Cannistra has developed over the past decade. Dr. Cannistra is a co-Principal Investigator on the DF/HCC Ovarian Cancer SPORE, serves as an Associate Editor and Medical Science Consulting Editor for the Journal of Clinical Oncology, and has served as program chair for the Gynecologic Cancer Committee of the American Society of Clinical Oncology (ASCO). He also serves on the Program Committee of the Society of Gynecologic Oncologists and is media spokesperson for ASCO in the fields of tumor biology and gynecologic malignancies. DISCLOSURE:

MARK S. HUBERMAN, MD Reviewer

Bio and Photo Coming Soon. DISCLOSURE:

TODD SHUSTER, MD Reviewer

Bio and Photo Coming Soon. DISCLOSURE:

ANDREW ZHU, MD, PHD Reviewer

Dr. Andrew X. Zhu is an attending Oncologist at Massachusetts General Hospital Cancer Center, a Staff Physician at Dana-Farber Cancer Institute, and a Member of Dana-Farber Harvard Cancer Center in Boston, Mass. He is also an Assistant Professor of Medicine at Harvard Medical School. Dr. Zhu is board-certified in internal medicine and medical oncology, and holds clinical research interests in developing novel treatments for gastrointestinal cancers including hepatocellular carcinoma, bile duct tumor, and colorectal cancer. Dr. Zhu received his medical degree from Beijing Medical University in China and his doctor of philosophy in microbiology from Columbia University in New York City. He completed his internship and residency in internal medicine at the University of Minnesota Hospitals and Clinics and Yale-New Haven Hospital. After a fellowship in molecular biology at Harvard Medical School, he was a Mortimer Lacher Fellow in medical oncology at Memorial Sloan-Kettering Cancer Center in New York City. As a widely published author, Dr. Zhu has served as principle investigator in many clinical trials in hepatobiliary and colorectal cancers and has published papers on many leading journals including the New England Journal of Medicine, Journal of Clinical Oncology, Clinical Cancer Research, and Cancer. He is a founding board member of the International Liver Cancer Association and a member of the American Society of Clinical Oncology, the American College of Physicians, and the American Association for Cancer Research. DISCLOSURE:

back to the top

NUMBER OF CREDITS: 5 

Harvard Medical School is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The Harvard Medical School designates this educational activity for a maximum of 5 AMA PRA Category 1 credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Upon completion of the course you will get a certificate via e-mail within 2 weeks.

Click the image to view a sample of the certificate

back to the top